5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
BUY | SELL | SELL | SELL | SELL |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 21.21▲ | 21.20▲ | 21.28▼ | 23.67▼ | 22.07▼ |
MA10 | 21.18▲ | 21.29▼ | 21.33▼ | 23.89▼ | 23.53▼ |
MA20 | 21.09▲ | 21.36▼ | 22.67▼ | 22.75▼ | 22.95▼ |
MA50 | 21.28▼ | 23.82▼ | 24.36▼ | 23.46▼ | 21.30▼ |
MA100 | 21.37▼ | 24.37▼ | 23.24▼ | 23.16▼ | 24.85▼ |
MA200 | 22.41▼ | 23.10▼ | 23.07▼ | 21.41▼ | 28.62▼ |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | 0.032▲ | 0.124▲ | -0.090▼ | -0.104▼ | -0.265▼ |
RSI | 55.067▲ | 34.155▼ | 31.807▼ | 40.336▼ | 47.051▼ |
STOCH | 79.902 | 43.253 | 22.001 | 51.576 | 43.490 |
WILL %R | 0.000▲ | -53.896 | -89.026▼ | -94.577▼ | -57.715 |
CCI | 110.595▲ | -42.108 | -53.927 | -80.391 | -61.877 |
Friday, June 13, 2025 10:02 AM
Phase 1 data shows encouraging safety and niche efficacy. Click here to find out why I maintain a buy rating for SDGR stock.
|
Thursday, June 12, 2025 05:00 PM
NEW YORK, May 29, 2025--Schrödinger, Inc. (Nasdaq: SDGR) today announced the grant of inducement equity awards to the company’s newly appointed EVP, Chief Commercial Officer, Global Head of ...
|
Thursday, June 12, 2025 08:05 AM
Schrödinger (SDGR) stock fell after Phase 1 trial data for SGR-1505 its experimental drug for B-cell malignancies. Read more here.
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
16/06/25 | 21.68 | 21.68 | 20.91 | 21.265 | 459,165 |
13/06/25 | 22.01 | 22.29 | 20.90 | 21.43 | 1,728,090 |
12/06/25 | 26.45 | 26.45 | 22.67 | 22.835 | 2,582,454 |
11/06/25 | 26.30 | 27.63 | 25.911 | 26.69 | 1,458,222 |
10/06/25 | 25.635 | 26.72 | 25.635 | 26.14 | 1,501,862 |
09/06/25 | 24.99 | 25.71 | 24.45 | 25.47 | 1,426,043 |
06/06/25 | 24.21 | 24.92 | 23.98 | 24.62 | 1,167,348 |
05/06/25 | 23.89 | 24.71 | 23.41 | 23.84 | 785,549 |
04/06/25 | 23.01 | 23.89 | 22.85 | 23.73 | 968,010 |
03/06/25 | 22.03 | 22.95 | 21.29 | 22.90 | 1,000,471 |
|
|
||||
|
|
||||
|
|